跳至主要内容
临床试验/NCT05234177
NCT05234177招募中不适用

Tempus CRC Surveillance Study: A Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Colorectal Cancer (CRC) Using Comprehensive Next-Generation Sequencing (NGS)Assays

Tempus AI20 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2022年6月21日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
Tempus AI
入组人数
300
试验地点
20
主要终点
Recurrence-Free Survival

研究概览

简要总结

The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Known or suspected colorectal adenocarcinoma (Stage I to IVA disease)
  • Planning to undergo or has undergone a surgical resection for suspected adenocarcinoma of the colon or rectum with curative intent.
  • 18 years old or older
  • Willing and able to provide informed consent
  • Willing to have additional blood samples collected during routine surveillance visits

排除标准

  • Not willing to have additional blood samples collected
  • Pathology that is not consistent with colorectal adenocarcinoma

结局指标

主要结局

Recurrence-Free Survival

时间窗: 2 years

Recurrence-Free Survival as assessed by standard radiographic imaging, measured from the day of completion of definitive treatment to first radiographic recurrence or death

次要结局

  • Sensitivity(2 years)
  • Positive Predictive Value(2 years)
  • Specificity(2 years)

研究者

发起方
Tempus AI
申办方类型
Industry
责任方
Sponsor

研究点 (20)

Loading locations...

相似试验